BIT Capital’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

BIT Capital’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-137,746	Closed	-$748K	–	184
2022 Q4	$748K	Buy	137,746 +114,547	+494%	+$960K	0.15%	52
2022 Q3	$290K	Buy	+23,199	New	+$265K	0.05%	112
2022 Q2	–	Sell	-5,000	Closed	-$38K	–	177
2022 Q1	$38K	Buy	+5,000	New	+$47.4K	﹤0.01%	121

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT Capital's GTHX Position: Q1 2023 in Review

BIT Capital sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 137,746 shares — an estimated $748K sold.

BIT Capital first reported a position in GTHX in Q1 2022 and held it in 3 quarters. The position peaked at $748K in Q4 2022. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

BIT Capital reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
BIT Capital sold 137,746 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $748K.
BIT Capital first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
BIT Capital's G1 Therapeutics, Inc. Common Stock position peaked at $748K in Q4 2022.
96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on BIT Capital's 13F filing for Q1 2023, filed 12 Feb 2025.